Objective: In addition to the increasingly recognized role of physical exercise in maintaining cognition, exercise may influence Alzheimer's disease (AD) pathology, as transgenic mouse studies show lowered levels of AD pathology in exercise groups. The objective of this study was to elucidate the association between exercise and AD pathology in humans using Pittsburgh compound-B (PIB), amyloid-b (Ab) 42 , tau, and phosphorylated tau (ptau) 181 biomarkers. Methods: Sixty-nine older adults (17 males, 52 females) aged 55 to 88 years, were recruited and confirmed to be cognitively normal. A questionnaire on physical exercise levels over the past decade was administered to all. Cerebrospinal fluid samples were collected from 56 participants, and amyloid imaging with PIB was performed on 54 participants. Results: Participants were classified based on biomarker levels. Those with elevated PIB (p ¼ 0.030), tau (p ¼ 0.040), and ptau 181 (p ¼ 0.044) had significantly lower exercise, with a nonsignificant trend for lower Ab 42 (p ¼ 0.135) to be associated with less exercise. Results were similar for PIB after controlling for covariates; tau (p ¼ 0.115) and ptau 181 (p ¼ 0.123) differences were reduced to nonsignificant trends. Additional analyses also demonstrated that active individuals who met the exercise guidelines set by the American Heart Association had significantly lower PIB binding and higher Ab 42 levels with and without controlling for covariates (PIB: p ¼ 0.006 and p ¼ 0.001; Ab 42 : p ¼ 0.042 and p ¼ 0.046). Last, the associations between exercise engagement and PIB levels were more prominent in APOE epsilon 4 noncarriers. Interpretation: Collectively, these results are supportive of an association between exercise engagement and AD biomarkers in cognitively normal older adults.
W
ith the disproportionate growth of the elderly population, Alzheimer's disease (AD)-the most common form of dementia among older adults-is poised to become a public health crisis. Although research on novel therapeutic strategies is gathering momentum with several new drugs entering clinical trials, it is still unclear what will be successful. 1 Coupled with the lack of current treatments that can halt this disease, there is great impetus toward efforts concerning early detection and prevention of AD. Lifestyle practices that could potentially deter or slow disease progression are especially important, considering that neurodegeneration in AD can begin a decade or more before the appearance of clinical symptoms. 2, 3 Physical exercise may be an effective tool in this regard, with its increasingly recognized role in preserving not only cardiovascular but also brain and cognitive health in older adults. 4 Recommended by the Alzheimer's Association 5 to clinicians as a way to maintain cognitive functioning in AD and enhance a patient's quality of life (eg, by lowering depression), studies now suggest that exercise may also reduce risk of cognitive decline and dementia.
There has been recent attention to how exercise affects AD pathology as quantified by imaging and neurochemical measures. The accumulation of amyloid plaques and neurofibrillary tangles involved in the neurodegenerative process of AD are correlated with several useful biomarkers. First, fibrillar amyloid-b deposition can be detected through positron emission tomography (PET) studies with Pittsburgh compound-B (PIB) as radiotracers to image the amyloid-b (Ab) aggregates, with plaque formation indicated by higher uptake of PIB. 8 In addition, amyloid deposition can be assayed using lumbar puncture to measure the cerebrospinal fluid (CSF) level of Ab 42 (a primary constituent of plaques), with reductions in CSF levels of Ab 42 indicative of plaque formation. Third, neurofibrillary tangles are composed of hyperphosphorylated tau proteins (ptau), and an increased CSF level of ptau 181 is observed in AD. 9 Last, AD axonal death and neuronal degeneration are reflected in atrophy of brain regions such as the hippocampus and increased CSF levels of normally intracellular tau protein. 10, 11 These biomarkers-PIB, Ab 42 , tau, ptau 181 , and magnetic resonance imaging (MRI) brain volumetry-chart AD pathology and may serve as early diagnostic indicators. 12, 13 Using these biomarkers, researchers have investigated the effects of physical exercise on structural brain integrity and AD pathology. Structural imaging studies indicate beneficial effects of exercise and aerobic fitness on brain structure in healthy older adults 14, 15 and individuals with AD. 16, 17 Investigations of the effects of environmental enrichment, including wheel running, in transgenic AD mouse models have demonstrated improvements in cognitive performance but varying results in terms of amyloid deposition, with reports of reduced, [18] [19] [20] stable, 21 and increased 22 levels. Examination of exercise specifically in transgenic AD mice has also produced discrepant results, with lower levels of amyloid deposition and lower tau observed in some investigations, [23] [24] [25] but no effect of exercise on amyloid reported by others. 26, 27 Divergent results in these studies may be attributable to use of different genetic mouse models, whether exercise onset is before or at the time of symptom onset, and/or type and duration of exercise. 28 The association between exercise and human AD pathology, however, as measured by PET-PIB and CSF neurochemical biomarkers such as Ab 42 , tau, and ptau 181 , remains unexplored. The primary goal of the current study was to examine associations between exercise engagement and biomarker levels in older adults without clinical symptoms of AD. 14 
Patients and Methods

Participants
Measurement of Physical Exercise Engagement
VALIDITY. A validated questionnaire assessing history of walking, running, and jogging (WRJ) activity for the past 10 years was used to estimate exercise engagement. 31 The measure was significantly correlated with cardiorespiratory fitness measured via treadmill test in a sample of 5063 individuals aged 18 to 80 years. Stable correlations were observed between retrospective self-report of activity for a particular year and aerobic fitness for that year across the 10 1-year assessment periods, suggesting that participants across the examined age range were capable of relatively accurate self-report over this extended time span.
PROCEDURE. The questionnaire was administered by telephone, and participants reported number of months/year, number of workouts/wk, average number of miles/workout, and average time/mile for each year in which they engaged in WRJ activity for the preceding 10 years. A physical exercise engagement score for each participant was derived by estimating metabolic equivalent (MET) values using the compendium of physical activities, 32 as described previously. 31 The index of exercise engagement was average MET hours/wk over the past 10 years. As a reference, an individual who followed the physical exercise recommendation of the American Heart Association (AHA) for older adults (30 minutes of moderate exercise 5 days/wk) would score 7.5 MET-hours/wk.
31,33
Cerebrospinal Fluid Collection, Processing, and Biomarker Measurement CSF (20-30ml) free from any blood contamination was collected by lumbar puncture in polypropylene tubes at 8:00 am after overnight fasting, as described previously. 8 Samples were gently inverted to avoid gradient effects, briefly centrifuged at low speed to pellet any cellular elements, and aliquoted (500ll) into polypropylene tubes before freezing at À84 C. Analyses for total tau, ptau 181 , and Ab 42 were completed using commercial enzyme-linked immunosorbent assay (Innotest; Innogenetics, Ghent, Belgium). For all biomarker measures, samples were continuously kept on ice with only a single thaw after initial freezing before assays.
PET-PIB Imaging
In vivo amyloid imaging via PET with PIB ([N-methyl- 
APOE Genotyping
TaqMan assays (Applied Biosystems Inc.
[ABI], Foster City, CA) for both rs429358 (ABI#C_3084793_20) and rs7412 (ABI#C_904973_10) were used for APOE genotyping. Allele calling was performed using the allelic discrimination analysis module of ABI Sequence Detection Software. Positive controls for each of 6 possible APOE genotypes were included on the genotyping plate. Individuals were then classified as e4þ (44, 34, 24) or e4À (33, 23, 22) depending on whether or not at least 1 e4 allele was present.
Diagnostic Biomarker Thresholds
Although use of CSF biomarker thresholds in determining risk of AD is prevalent, standard diagnostic cutoff values are lacking, as noted previously. 35 This study used a PIB cutoff of 0.20 MCBP, because regional brain atrophy in cognitively normal individuals with PIB levels at or above this level has been demonstrated. 13 Individuals with MCBP ! 0.20 were considered PIBþ (''at risk'' phenotype); those below this cutoff were considered PIBÀ (''normal'' phenotype). For CSF Ab 42 , 500pg/ml was chosen, as this level is indicative of brain amyloid as assessed by PET-PIB, 8, 36 and is associated with whole brain and hippocampal atrophy in cognitively normal individuals. 37 For CSF tau and ptau 181 , there was less precedent in existing literature for predetermined cutoffs, as a wide range of values are reported to distinguish AD from controls with no clear guidelines. 9, 35 Therefore, we plotted the data, and as apparent in the Figure, C-D, there was a behavior that seemed to be best expressed with tau and ptau 181 thresholds of 425pg/ml and 72pg/ml, respectively, which are within the range of diagnostic values reported previously. 35, 36 Individuals with low CSF Ab 42 (<500pg/ml, ''at risk'') were considered Ab 42 þ; those with high Ab 42 (!500pg/ml, ''normal'') were considered Ab 42 À. Similarly, those with CSF tau and ptau 181 values above the cutoffs were classified as tauþ and ptau 181 þ (''at risk''), respectively; those below the cutoffs were classified tauÀ and ptau 181 À (''normal'').
Statistical Analyses
All analyses were conducted using SPSS/PASW 17.0 (SPSS Inc., Chicago, IL). All statistical significance tests were 2-tailed, with a ¼ 0.05. We first tested for group differences in demographic variables, APOE status, and medical conditions using Student t tests for continuous variables and chi-square or Fisher exact test for dichotomous variables (Tables 1 and 2 ). With 2 exceptions (see Table 1 and Results section), there were no significant differences between biomarker groups or between exercise groups. Primary questions regarding associations between exercise and biomarkers were examined with Student t test for groups with equal variance; unequal variance t tests were used when the assumption of equal variances was unmet. Although age, gender, and education were not significantly associated with dependent variables (with 2 exceptions noted above), analyses were also conducted controlling for these potentially confounding factors. In these analyses, residuals of the dependent variable after adjustment for age, gender, and education were submitted to t tests. Values !3 SD from the mean were considered outliers. Unless otherwise specified in the Results section, results were unchanged when outliers were removed. 
Results
Individuals with
At-Risk Biomarker Levels Evidence Less Exercise Engagement Examination of graphs plotting exercise engagement against biomarker levels (see Fig) suggests that0.040 and t[29.9] ¼ 2.104, p ¼ 0.044, respectively). However
Exercise Effects by APOE Genotype
There were significant differences in Ab 42 levels depending on APOE genotype, with e4þ individuals having lower Ab 42 levels (e4þ: 564pg/ml; e4À: 679pg/ml; t[54] ¼ 2.024, p ¼ 0.048). There was also a nonsignificant trend for e4þ individuals to have higher MCBP (e4þ: 0.214, e4: 0.048; t[15.8] ¼ À2.070, p ¼ 0.055). There were, however, no significant differences in tau or ptau 181 levels depending on APOE genotype (tau, e4þ: 303pg/ml, e4À: 264pg/ml, t[54] ¼ À1.021, p ¼ 0.312; and ptau 181 , e4þ: 58pg/ml, e4À: 50pg/ml, t (54) ¼ À1.337, p ¼ 0.187). Therefore, we examined the relationship between exercise and amyloid deposition separately for e4þ and e4À groups (see Tables 1 and 2 for sample sizes).
For the e4À group, there was a nonsignificant trend for PIBÀ individuals to report greater exercise (t [7. 
Discussion
Emerging evidence from human structural imaging and AD transgenic mouse studies suggests physical exercise may have beneficial effects on AD-related pathology and/ or cognition. 16, 17, [23] [24] [25] [26] [27] The purpose of the current investigation was to extend this knowledge base to include human findings regarding exercise engagement and biomarkers, including amyloid deposition measured with PET-PIB and CSF levels of Ab 42 , tau, and ptau 181 . We observed novel associations between exercise engagement and biomarker levels in cognitively normal older adults. Visual inspection of graphs plotting exercise engagement against biomarker levels suggests strong associations, with individuals dispersed in an L-shaped distribution (see Fig). Most notable is that at one end of the distribution, individuals with greater physical exercise have lower MCBP, CSF tau, and ptau 181 , or higher CSF Mean education, yr (SD) 16 (6) 16 (3) 17 (4) 15 (3) 16 (4) 16 (3) 16 (4) Ab 42 , whereas individuals with at-risk levels of biomarkers at the other end of the distribution are all relatively sedentary. This observation was somewhat confirmed by comparing exercise scores of those with at-risk biomarker levels against those with normal levels. Participants with elevated MCBP, tau, or ptau 181 exercised significantly less, and there was a nonsignificant trend for lower exercise in those with decreased Ab 42 . However, associations for tau and ptau 181 were reduced to nonsignificant trends with age, gender, and education controlled, suggesting that these variables accounted for a portion of the variance despite the lack of significant group differences in these variables. Past research indicates that cognitively normal individuals who are PIBþ exhibit regional brain atrophy and longitudinal cognitive decline compared to PIBÀ individuals. 13 In addition, reduced CSF Ab 42 in cognitively normal individuals has been associated with whole brain and hippocampal atrophy in cognitively normal individuals 37 and elevated MCBP. 8, 36 Collectively, results are suggestive of differing levels of exercise across biomarker status, such that individuals potentially at greater risk for AD engaged in less exercise.
Comparing biomarker levels of those who did or did not meet AHA exercise guidelines provided further insights into associations between exercise and AD pathology. Active individuals exhibited significantly lower MCBP and higher CSF Ab 42 levels. However, no differences in tau and ptau 181 levels were found between exercise groups. This may be attributable to alterations in tau and ptau 181 potentially occurring subsequent to amyloid plaque formation later in the course of AD disease progression, [37] [38] [39] thereby resulting in less evident exercise effects on these biomarkers in a cognitively normal population. Past research is suggestive that beneficial effects of exercise on tau levels in a transgenic mouse model may be observed at the time at which tau is typically expressed. 24 Current findings for MCBP and Ab 42 do converge to suggest that greater exercise engagement is associated with healthier amyloid profiles. Previous investigations have observed elevated levels of amyloid and tau as measured by PET-PIB and PETfluorine-18 2-dialkylamino-6-acylmalononitrile substituted naphthalenes (PET-FDDND) in cognitively normal adults with an APOEe4 allele. 40, 41 In this study, e4þ
individuals displayed elevated MCBP and lowered Ab 42 , Exercise groups are based on the American Heart Association's recommended exercise levels (see text for details). but no differences in tau or ptau 181 . In separate analyses of associations between amyloid and exercise for e4þ and e4À groups, results for e4À, but not for e4þ, individuals essentially mirrored findings in the full sample for MCBP. Considering that past literature indicates greater exerciserelated benefits for cognition for e4þ individuals, 6 ,42-44 a larger exercise effect on biomarkers in this group might be expected. It is notable that in the current study, although mean exercise scores did not significantly differ between e4þ and e4À individuals, there were fewer e4þ individuals exercising at AHA recommended levels (see Table 2 ). Therefore, there is some indication that presence of this risk factor for AD (and altered biomarker levels) may lead to reduced exercise levels. Beneficial effects of exercise on cognition in e4þ individuals observed previously may relate to mechanisms other than direct effects on neuropathology, such as increased brain-derived neurotrophic factor and synaptogenesis. 45 Current analyses are limited by differential sample sizes between the e4þ and e4À groups. It would be of particular interest to determine whether gene Â environment interactions exist such that exercise actually moderates associations between e4þ status and greater amyloid deposition in larger samples.
Although current results suggest a relatively robust relationship between exercise engagement and examined AD biomarkers, particularly in terms of amyloid levels, the direction of causality between exercise and human AD pathology remains uncertain, considering our crosssectional design. Furthermore, the current self-report measure of exercise engagement is significantly but not perfectly related to cardiorespiratory fitness, and may also be limited by the ability of older adults to accurately recall and report their exercise over a 10-year span. In addition, although our exercise measure captured engagement at the PET-PIB or CSF assessment for most participants, it is possible that exercise behavior changes occurred for individuals whose PET-PIB or CSF assessment followed measurement of exercise engagement. The study is also limited by the lack of well-established, research-guided thresholds for determining at-risk levels of biomarkers, particularly for tau and ptau 181 , and also by the relatively small sample size. To further elucidate whether physical exercise directly deters AD pathology, an interventional study in cognitively normal and AD individuals is needed. Future investigations might also include cognitive and brain atrophy outcome measures while comparing combinations of exercise, social, and cognitive interventions. 46 The novel findings of this study, in conjunction with positive results in transgenic AD mouse models, suggest a further rationale for clinicians to prescribe exercise regimens as not only symptomatic relief for AD patients, but as potentially preventive care as well.
